

Reviewed: 11/13/24

Revised: 04/01/25

Preferred Agents and Drug List

Rheumatoid Disorders

Disease State	Step 1A	Step 1B	Step 2	Step 3A	Step 3B	Step 3C
		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Ankylosing Spondylitis (AS)	SC: Adalimumab products**, Cosentyx, Enbrel	Oral: Rinvoq, Xeljanz, Xeljanz XR	N/A	SC: Cimzia, Simponi, Taltz	N/A	SC: Bimzelx
Nonradiographic Axial Spondyloarthritis (nr-axSpA)	SC: Cimzia, Cosentyx	Oral: Rinvoq	N/A	SC: Taltz	N/A	SC: Bimzelx
Polyarticular Juvenile Idiopathic Arthritis (PJIA)	SC: Adalimumab products**, Enbrel	Oral: Rinvoq, Rinvoq LQ, Xeljanz	SC: Tyenne (an adalimumab product** is a required Step 1 agent)	SC: Cimzia	SC: Actemra (an adalimumab product** AND Tyenne are required Step 1 agents), Orenzia	SC: Kevzara
Psoriatic Arthritis (PsA)	SC: Adalimumab products**, Cosentyx, Enbrel, Skyrizi, Stelara, Tremfya Oral: Otezla	Oral: Rinvoq, Rinvoq LQ, Xeljanz, Xeljanz XR	N/A	SC: Cimzia, Orenzia, Simponi, Taltz	N/A	SC: Bimzelx
Rheumatoid Arthritis (RA)	SC: Adalimumab products**, Enbrel	Oral: Rinvoq, Xeljanz, Xeljanz XR	SC: Tyenne (an adalimumab product** is a required Step 1 agent)	SC: Cimzia, Kevzara, Orenzia, Simponi Oral: Olumiant	SC: Actemra (an adalimumab product** AND Tyenne are required Step 1 agents)	SC: Kineret
Systemic Juvenile Idiopathic	SC: Tyenne	N/A	SC: Actemra	N/A	N/A	N/A

Arthritis (SJIA)						
------------------	--	--	--	--	--	--

Dermatological Disorders

Disease State	Step 1A	Step 1B	Step 2	Step 3A	Step 3B	Step 3C
		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Hidradenitis Suppurativa (HS)	SC: Adalimumab product(s)**, Cosentyx	N/A	N/A	N/A	N/A	SC: Bimzelx
Psoriasis (PS)	SC: Adalimumab product(s)**, Cosentyx, Enbrel, Skyrizi, Stelara, Tremfya Oral: Otezla, Sotyktu	N/A	N/A	SC: Cimzia	N/A	SC: Bimzelx, Siliq, Taltz

Inflammatory Bowel Disease

Disease State	Step 1A	Step 1B	Step 2	Step 3A	Step 3B	Step 3C
		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Crohn's Disease (CD)	SC: Adalimumab product(s)**, Entyvio, Skyrizi, Stelara	Oral: Rinvoq	SC: Omvoh	SC: Cimzia, Zymfentra	N/A	N/A
Ulcerative Colitis (UC)	SC: Adalimumab product(s)**, Entyvio, Skyrizi, Stelara, Tremfya	Oral: Rinvoq Xeljanz Xeljanz XR	SC: Omvoh, Simponi (an adalimumab product** is a required Step 1 agent)	SC: Zymfentra Oral: Zeposia	N/A	Oral: Velsipity

Other

Disease State	Step 1A	Step 1B	Step 2	Step 3A	Step 3B	Step 3C
---------------	---------	---------	--------	---------	---------	---------

		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Giant Cell Arteritis (GCA)	SC: Tyenne	N/A	SC: Actemra	N/A	N/A	N/A
Systemic Sclerosis- associated Interstitial Lung Disease (SSc-ILD)	SC: Tyenne	N/A	SC: Actemra	N/A	N/A	N/A
Uveitis	SC: Adalimumab product(s)**	N/A	N/A	N/A	N/A	N/A

Indications Without Prerequisite Biologic Immunomodulators Required

Disease State	Step 1A	Step 1B	Step 2	Step 3A	Step 3B	Step 3C
		Directed to ONE (1) TNF inhibitor NOTE: See Step 1a for preferred TNF inhibitors	Directed to ONE (1) Step 1 agent	Directed to TWO (2) Step 1 agents	Directed to TWO (2) agents from Step 1 and/or Step 2	Directed to THREE (3) Step 1 agents
Alopecia Areata (AA) Atopic Dermatitis (AD) Deficiency of IL- 1 Receptor Antagonist (DIRA) Enthesitis Related Arthritis (ERA) Juvenile Psoriatic Arthritis (JPsA) Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Polymyalgia Rheumatica (PMR)	N/A	N/A	N/A	N/A	N/A	N/A

**Allowable preferred adalimumab product(s): adalimumab-aaty, adalimumab-adaz, Hadlima, Humira, Simlandi.

Note: For Xeljanz products (Xeljanz and Xeljanz XR) and Rinvoq products (Rinvoq and Rinvoq LQ), a trial of either or both dosage forms collectively counts as **ONE** product.

UPDATE INFORMATION:

01/01/25	New document.
04/01/25	Revision. Omvoh added as a Step 2 agent for CD. Cimzia moved from a Step 3c agent to a Step 3a agent for PJIA. Cimzia for CD no longer always requires an adalimumab product as a required Step 1 agent.